GNPX: Genprex Inc. Sof marja

Genprex Inc. (GNPX) korporativ emblemasi va logotipi

GURU.Markets tizimi grafigidagi savdo marjasi trayektoriyasi shuni ko'rsatadiki, Genprex, Inc. (GNPX) hozirda 0.00 darajasida turibdi. Ushbu tendentsiya R&D xarajatlarini nazorat ostida ushlagan holda, o'pka terapiyasi bo'yicha FDA sinovlaridan o'tishga bog'liq. Genprex, Inc. (GNPX) genlarni yetkazib berish uchun nanoparticles ishlab chiqishga tayanadi, onkologiya va diabet o'rtasidagi pipeline diversifikatsiyasi esa biznesning tartibga soluvchi xatarlarini minimallashtiradi.

genprex.com (GNPX) - Sof marja 04.07.2022dan 19.11.2026gacha

Genprex, Inc (GNPX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Kompaniyaning barcha koʻrsatkichlari tahlili:Genprex, Inc.
Genprex Inc. tayyor mahsulotlari

Sotuv marjalari barcha xarajatlardan keyin qolgan kapitalni tahlil qilish orqali emitentning investitsiya barqarorligini belgilaydi. Ushbu metrika tushumda sof foydaning ulushini o'lchaydi va daromadni erkin pul oqimiga aylantirishning haqiqiy samaradorligini aks ettiradi. Maqsadli sof marjallardagi tendentsiya operatsion o'sishni bir martalik moliyaviy effektlardan ajratish imkonini beradi. Genprex, Inc. (GNPX) uchun ushbu ko'rsatkich gen terapiyasi ishlab chiqish davrida hal qiluvchi ahamiyatga ega. FDA tasdiqlari investitsiya bosqichidan mahsulotlarning tizimli monetizatsiyasiga o'tish uchun katalizator vazifasini o'taydi.

Muhim raqobatchilar

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|ANL - Sof marja|Sof marja verupharma.com|TPST: Sotuvning sof marjinal rentabelligi|XLO - Kompaniya sotuv marjasi|Sof marja Renovaro|Sotuvning sof marjinal rentabelligi muraloncology.com|Sotuvning sof marjinal rentabelligi KAPA|Kompaniya sotuv marjasi OnKure Therapeutics, Inc.|Sotuvning sof marjinal rentabelligi GDTC (w2.cytomed.sg)|CRIS - Sof foyda bo'yicha sotuv rentabelligi|Apollomics - Sotuvning sof marjinal rentabelligi|Tharimmune Corp (THAR) - Sof foyda bo'yicha sotuv rentabelligi|ADVB: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)